Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Gliclazide 80mg Tablets
NCT02643329Phase 1Completed
- Sponsor
- Bright Future Pharmaceutical Laboratories Limited
- Start
- Jan 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gliclazide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bright Future Pharmaceutical Laboratories Limited. Primary endpoints: Peak Plasma Concentration at 72 hours and Area Under the Curve at 72 hours. Started Jan 2016; status: completed.
02
Drugs
gliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02643329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643329.